Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 31, 2023

BUY
$3.02 - $4.05 $4,146 - $5,560
1,373 Added 4.76%
30,220 $92,000
Q2 2023

Jul 19, 2023

SELL
$2.79 - $5.03 $7,976 - $14,380
-2,859 Reduced 9.02%
28,847 $95,000
Q1 2023

May 12, 2023

BUY
$3.14 - $8.22 $25,760 - $67,436
8,204 Added 34.91%
31,706 $101,000
Q4 2022

Feb 10, 2023

BUY
$5.77 - $8.49 $135,606 - $199,531
23,502 New
23,502 $163,000
Q2 2022

Aug 09, 2022

SELL
$2.94 - $5.23 $41,783 - $74,328
-14,212 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$4.07 - $10.6 $5,677 - $14,787
1,395 Added 10.88%
14,212 $69,000
Q4 2021

Feb 10, 2022

BUY
$8.96 - $16.31 $17,955 - $32,685
2,004 Added 18.53%
12,817 $128,000
Q3 2021

Nov 09, 2021

BUY
$11.24 - $21.0 $24,593 - $45,948
2,188 Added 25.37%
10,813 $207,000
Q2 2021

Aug 05, 2021

BUY
$18.04 - $22.09 $23,433 - $28,694
1,299 Added 17.73%
8,625 $276,000
Q1 2021

May 11, 2021

BUY
$16.59 - $33.89 $22,429 - $45,819
1,352 Added 22.63%
7,326 $221,000
Q4 2020

Feb 11, 2021

BUY
$27.5 - $37.92 $61,737 - $85,130
2,245 Added 60.2%
5,974 $258,000
Q3 2020

Nov 02, 2020

BUY
$34.44 - $43.75 $128,426 - $163,143
3,729 New
3,729 $201,000
Q4 2018

Mar 04, 2019

SELL
$59.1 - $93.26 $371,916 - $586,885
-6,293 Closed
0 $0
Q3 2018

Nov 09, 2018

SELL
$88.86 - $117.49 $341,844 - $451,984
-3,847 Reduced 37.94%
6,293 $919,000
Q2 2018

Aug 06, 2018

SELL
$99.64 - $127.59 $76,025 - $97,351
-763 Reduced 7.0%
10,140 $1.59 Million
Q1 2018

May 08, 2018

SELL
$105.8 - $150.94 $473,984 - $676,211
-4,480 Reduced 29.12%
10,903 $1.86 Million
Q4 2017

Feb 06, 2018

BUY
$81.25 - $130.7 $950,300 - $1.53 Million
11,696 Added 317.22%
15,383 $2.74 Million
Q3 2017

Nov 06, 2017

BUY
$57.74 - $91.42 $212,887 - $337,065
3,687
3,687 $506,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $28.5M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.